List of Excipients in Branded Drug SEVELAMER CARBONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	SEVELAMER CARBONATE	sevelamer carbonate	0955-1050	CELLULOSE, MICROCRYSTALLINE
Sanofi-Aventis US LLC	SEVELAMER CARBONATE	sevelamer carbonate	0955-1050	DIACETYLATED MONOGLYCERIDES
Sanofi-Aventis US LLC	SEVELAMER CARBONATE	sevelamer carbonate	0955-1050	FERROSOFERRIC OXIDE
Sanofi-Aventis US LLC	SEVELAMER CARBONATE	sevelamer carbonate	0955-1050	HYPROMELLOSE

Generic Drugs Containing SEVELAMER CARBONATE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	sevelamer carbonate	0115-1365	LEMON
Amneal Pharmaceuticals of New York LLC	sevelamer carbonate	0115-1365	MICROCRYSTALLINE CELLULOSE 102
Amneal Pharmaceuticals of New York LLC	sevelamer carbonate	0115-1365	PROPYLENE GLYCOL ALGINATE
Amneal Pharmaceuticals of New York LLC	sevelamer carbonate	0115-1365	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in SEVELAMER CARBONATE?

# Of NDCs	Excipient
19	AMMONIA
5	CARNAUBA WAX
2	CASTOR OIL
28	CELLULOSE, MICROCRYSTALLINE

Sevelamer Carbonate Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Sevelamer carbonate is a mature, nonabsorbed phosphate binder with limited active-ingredient differentiation. Commercial value is concentrated in formulation execution: tablet size, powder palatability, dispersion, dose flexibility, gastrointestinal tolerability, packaging, and manufacturing efficiency. The strongest opportunities are generic substitution, pediatric and dysphagia-friendly presentations, hospital and dialysis-channel supply, and excipient systems that improve handling without reducing phosphate-binding performance.

What is the commercial position of sevelamer carbonate?

Sevelamer carbonate is a crosslinked, nonabsorbed polymer that binds dietary phosphate in the gastrointestinal tract. It is marketed primarily as Renvela by Genzyme, a Sanofi company, in tablets and powder for oral suspension. The product is indicated for control of serum phosphorus in adults with chronic kidney disease on dialysis and in pediatric patients aged six years and older with chronic kidney disease on dialysis [1].

Product attribute	Commercial implication
Active ingredient	Sevelamer carbonate, a nonabsorbed anion-exchange polymer
Main use	Hyperphosphatemia in chronic kidney disease
Administration	With meals; dosing is meal- and phosphorus-dependent
Dosage forms	800 mg and 2.4 g tablets; powder for oral suspension
Key burden	High daily pill count and gastrointestinal adverse effects
Main competitors	Calcium carbonate, calcium acetate, ferric citrate, sucroferric oxyhydroxide, lanthanum carbonate
Regulatory route for generics	ANDA, subject to product-specific requirements
Differentiation space	Formulation, dose flexibility, palatability, packaging, adherence and supply reliability

Sevelamer carbonate has commercial advantages over calcium-based binders because it does not add calcium and does not carry the same concern about calcium loading. Its disadvantages include large tablets, frequent administration, constipation, nausea, abdominal discomfort and adherence challenges. These characteristics make excipient strategy commercially relevant even though the active ingredient is mature.

What excipients are used in sevelamer carbonate products?

The reference product uses conventional solid-dose and powder-formulation excipients. Product labels identify inactive ingredients such as microcrystalline cellulose, colloidal silicon dioxide, stearic acid, hypromellose, sodium chloride and sucralose, depending on the dosage form and presentation [1,2].

The exact excipient composition differs between tablets and powder. The commercial objective is not rapid drug release. Sevelamer carbonate acts locally by binding phosphate, so the formulation must disperse or hydrate adequately in gastrointestinal contents while retaining polymer integrity and binding capacity.

Tablet excipient functions

Excipient class	Typical function	Sevelamer-specific consideration
Microcrystalline cellulose	Filler, compression aid, tablet structure	Must support high-load tablets without excessive hardness or slow hydration
Colloidal silicon dioxide	Glidant, flow aid	Useful for powder flow but can affect blend uniformity and dusting
Stearic acid	Lubricant	Excessive hydrophobic lubrication can delay wetting and polymer hydration
Hypromellose	Binder or matrix-forming aid	Can improve mechanical strength but may slow dispersion if overused
Sodium chloride	Osmolality and taste adjustment in powder	Must not compromise powder flow or moisture stability
Sucralose	Sweetener	Supports palatability in suspension products
Colorants	Product identification	Must be controlled for elemental impurities and regional acceptability

Excipient selection must account for the polymer’s cationic binding behavior. Calcium, magnesium, aluminum, iron and other multivalent cations can interact with phosphate or with the polymer system. Such materials require a specific compatibility assessment rather than routine substitution.

Which excipients are strategically attractive?

The most attractive excipient programs are those that improve administration without changing the sevelamer carbonate polymer itself.

Low-risk, near-term opportunities

Microcrystalline cellulose optimization, low-moisture granulation, and controlled lubricant addition offer the most practical route to manufacturing improvement. These changes can reduce tablet weight variability, improve compression, and lower the risk of capping or lamination.

Silicon dioxide can improve flow in direct-compression or roller-compacted blends. Its level must be balanced against segregation and airborne dust. A lower-dust, engineered grade may offer a manufacturing benefit without creating a new clinical claim.

Hypromellose can improve tablet integrity and powder suspension behavior. Its concentration and viscosity grade should be selected to avoid delayed wetting. Sevelamer carbonate is not a conventional immediate-release small molecule, so standard dissolution optimization is not the principal performance target. Hydration, dispersion and phosphate-binding kinetics are more relevant.

Higher-value formulation opportunities

Taste-masking systems have commercial value in powder products. Sucralose is established, but flavor systems, acidulants and mouthfeel modifiers can improve acceptability for pediatric and dialysis patients. The formulation must avoid excessive sweetness, sedimentation, clumping and poor redispersion.

Suspension stabilizers may improve dose uniformity in powder presentations. However, a thickened suspension can be difficult to swallow and may increase residue in cups or oral syringes. The target should be rapid dispersion with limited settling rather than a highly viscous suspension.

Effervescent or rapidly dispersible approaches could reduce preparation time, but they introduce acid-base and moisture risks. Carbonate-containing systems can change local pH and may interact with the polymer or alter phosphate-binding performance. This strategy requires extensive comparative in vitro data and has greater regulatory risk than conventional powder formulation.

Excipient strategies that require caution

Phosphate-containing excipients are commercially unattractive because they may add phosphorus to the administered dose and create analytical or labeling complications. Calcium, magnesium, aluminum and iron salts are also problematic because they may compete for phosphate or alter the binding environment.

Polyethylene glycol, surfactants and high levels of ionic polymers may improve wetting but can change polymer swelling, suspension behavior or binding kinetics. Their use should be supported by comparative phosphate-binding studies across physiologically relevant pH conditions.

What formulations are protected by sevelamer carbonate patents?

The principal formulation opportunity is now generic and product-improvement competition rather than protection of a new chemical entity. Patent protection historically covered sevelamer polymers, carbonate salt forms, pharmaceutical compositions and methods for treating hyperphosphatemia. The FDA Orange Book and relevant patent records identify the listed patents and expiration information for approved products [3].

A commercial review should separate four patent categories:

1. Polymer composition patents. These cover crosslinked amine-containing polymers and their structural parameters.
2. Salt-form patents. These distinguish sevelamer carbonate from sevelamer hydrochloride.
3. Dosage-form patents. These may cover tablets, powders, suspension systems, particle sizes, compression methods or excipient combinations.
4. Method-of-use patents. These may cover treatment of hyperphosphatemia, dosing in specific populations or administration regimens.

For a generic sevelamer carbonate product, the main freedom-to-operate risk is usually formulation and process overlap rather than basic use of sevelamer carbonate. A product may avoid a formulation claim through different excipient concentrations, granulation conditions, particle-size distribution or packaging configuration. That analysis requires claim-by-claim review of active patents in each target jurisdiction.

When does sevelamer carbonate lose exclusivity?

U.S. market exclusivity for sevelamer carbonate has substantially expired, and generic sevelamer carbonate products have entered the market. The relevant commercial issue is no longer the end of reference-product exclusivity. It is the scope of any surviving formulation, process or method-of-use patents and the practical timing of generic approval.

FDA-approved generic competition has reduced the ability to compete solely on price. A new entrant needs either a lower-cost manufacturing platform, reliable supply, a differentiated presentation, or channel-specific contracting.

Exclusivity factor	Current commercial relevance
New chemical entity exclusivity	Expired
Reference-product market exclusivity	Expired or no longer the primary barrier
Orange Book patents	Must be reviewed for each product and jurisdiction
Paragraph IV risk	Relevant for any unexpired listed patent
Pediatric exclusivity	Historical relevance; does not create a current broad barrier
Regulatory differentiation	More important than exclusivity for new entrants

What is the Orange Book status of sevelamer carbonate?

Sevelamer carbonate products approved under NDAs and ANDAs are evaluated through FDA labeling and Orange Book records. Orange Book listings can change as patents expire, are delisted, or become subject to litigation. A current diligence review should distinguish:

• Renvela NDA listings from generic ANDA products.
• Patents listed for tablets versus powder.
• Active patents from expired patents.
• Product-specific patents from patents that cover broader sevelamer compositions.
• Patent certifications submitted by each ANDA applicant.

Paragraph IV certifications can trigger Hatch-Waxman litigation and a potential 30-month stay. The commercial impact depends on whether the patent is likely to survive, whether the generic applicant receives a first-filer position, and whether the product can launch at risk.

Which companies are challenging or competing with Renvela?

Competition exists at both the generic and therapeutic levels.

Generic sevelamer carbonate competitors

Generic manufacturers compete through:

• Lower tablet cost.
• Powder presentations.
• Supply contracts with dialysis providers.
• Retail and specialty-pharmacy distribution.
• Formulation similarity that supports substitution.
• Manufacturing redundancy and dependable inventory.

The principal barriers are not active-ingredient discovery. They are scale, quality-system performance, high-volume tablet production, packaging, and reimbursement access.

Therapeutic competitors

Product	Active ingredient	Differentiation from sevelamer carbonate
Renagel	Sevelamer hydrochloride	Earlier sevelamer salt; chloride load is a consideration
Calcium acetate	Calcium salt	Low cost but adds calcium
Calcium carbonate	Calcium salt	Low cost and broad availability
Auryxia	Ferric citrate	Iron-based binder with potential iron-related considerations
Velphoro	Sucroferric oxyhydroxide	Chewable formulation and lower pill burden in some regimens
Fosrenol	Lanthanum carbonate	Chewable tablet; metal-based binder

Sevelamer carbonate remains attractive for patients in whom calcium loading is undesirable. It is less attractive when pill burden, swallowing difficulty or gastrointestinal tolerability drives treatment decisions.

How can excipient strategy reduce pill burden?

Excipients cannot materially increase the intrinsic phosphate-binding capacity of sevelamer carbonate without changing the active polymer or dose. They can, however, improve the usable dose.

Commercially relevant approaches include:

• Higher-density tablets that preserve the labeled polymer dose in a smaller unit.
• Improved compression to reduce tablet dimensions.
• Powder sachets that permit dose titration.
• Oral suspension systems that reduce swallowing burden.
• Unit-dose packaging that supports meal-based administration.
• More robust tablets that reduce chipping and dose loss during transport.
• Flavor and mouthfeel systems that improve powder acceptance.

A lower tablet count is commercially meaningful because sevelamer is often taken with each meal and may require multiple tablets per meal. The formulation must demonstrate dose uniformity and phosphate-binding equivalence rather than rely on tablet-size claims alone.

What regulatory evidence is needed for a new sevelamer carbonate formulation?

A generic product must satisfy FDA ANDA requirements and product-specific expectations. Sevelamer carbonate presents special analytical issues because it is a nonabsorbed polymer rather than a conventional systemically absorbed drug.

Relevant evidence includes:

• Assay and content uniformity for sevelamer carbonate.
• Polymer identity and degree of substitution.
• Particle-size distribution.
• Swelling and hydration behavior.
• Phosphate-binding capacity.
• Binding kinetics across relevant pH conditions.
• Comparative performance against the reference product.
• Dose uniformity after suspension preparation.
• Sedimentation and redispersion data for powders.
• Stability under temperature and humidity stress.
• Extractables, leachables and elemental impurity assessment.
• Microbial quality for powder and suspension products.
• Compatibility with common co-administered medicines.

FDA labeling instructs patients to take sevelamer carbonate with meals and separates administration of certain medicines because the polymer can reduce absorption of concomitant drugs [1]. A new excipient system must not expand this interaction risk.

What manufacturing and intellectual-property barriers exist?

The strongest manufacturing barriers are process consistency and analytical control.

Sevelamer carbonate tablets contain a high proportion of polymeric active material. The blend may have poor flow, variable compressibility and sensitivity to lubrication. Direct compression may be efficient but can produce weight and hardness variability. Wet granulation can improve flow but introduces moisture and drying controls that may affect polymer properties.

Key process variables include:

• Polymer particle size.
• Moisture content.
• Mixing order and duration.
• Lubricant level and mixing time.
• Compression force.
• Tablet porosity and hardness.
• Milling and sieve conditions.
• Powder filling accuracy.
• Packaging moisture barrier.

Packaging is part of the formulation strategy. High-barrier bottles, desiccants and unit-dose sachets can protect powder flow, prevent clumping and preserve dose uniformity. A packaging change may create a commercial advantage even where the excipient composition remains conventional.

Patent barriers may arise from process claims covering polymer manufacture, particle size, tablet compression, powder preparation or suspension stability. A non-infringing process can still be commercially unattractive if it has low yield, high solvent use, difficult cleaning validation or poor scale-up performance.

What licensing deals and partnership opportunities exist?

Publicly visible commercial value is concentrated in the reference product and generic supply arrangements rather than major recent licensing transactions. The most realistic partnership opportunities are:

• Contract manufacturing of tablets or powder sachets.
• Regional commercialization rights for generic sevelamer carbonate.
• Excipient-supplier partnerships for direct compression and taste masking.
• Dialysis-provider supply agreements.
• Co-development of pediatric or dysphagia-friendly presentations.
• Private-label products for hospital and specialty-pharmacy channels.

An excipient supplier can capture value by offering a qualified formulation platform rather than a single excipient. The platform should include compaction data, suspension performance, stability data, impurity profiles and scale-up support.

How strong is the sevelamer carbonate patent estate?

The estate is commercially weaker than it was during the launch period because the core product is mature and generic competition exists. Its residual strength depends on the jurisdiction and the specific claim type.

Patent category	Relative strength for a new entrant
Core sevelamer composition	Low to moderate, depending on jurisdiction and surviving claims
Carbonate salt form	Low to moderate
Conventional tablet excipients	Generally low unless claims are narrow and specific
Specialized suspension or taste-masking system	Moderate if technically distinctive
Manufacturing process	Moderate to high if difficult to design around
Pediatric dosing method	Variable and jurisdiction-specific
Packaging or stability claims	Usually moderate, with limited market value unless essential

A differentiated powder, lower-burden tablet or pediatric formulation can generate new intellectual property. The claims should focus on measurable technical features such as particle-size distribution, suspension redispersion time, binding kinetics, tablet dimensions, stability thresholds or specific excipient ratios. Broad claims to routine excipients are unlikely to provide durable protection.

What generic launch scenarios exist?

Low-cost conventional tablet launch

This is the fastest and lowest-risk pathway. The product closely follows the reference presentation and competes through manufacturing cost and contracting. Margins are likely to compress as more suppliers enter.

Powder-focused launch

A powder product can target patients with dysphagia and caregivers who need flexible dosing. Commercial success depends on palatability, preparation simplicity, sachet economics and reimbursement treatment.

Pediatric formulation launch

A pediatric product can address dose titration, swallowing limitations and caregiver administration. The opportunity is narrower than the adult market but may support stronger channel relationships and differentiated branding.

Premium adherence platform

A smaller tablet, improved suspension, dose-tracking package or meal-linked unit-dose system could command a premium if it produces measurable adherence or persistence benefits. The evidence burden is higher, and reimbursement may not recognize the added value.

What is the revenue exposure to sevelamer carbonate?

Revenue exposure is concentrated in the chronic dialysis population. Sevelamer is used chronically, but prescription volume is sensitive to dialysis-center purchasing, generic substitution, payer formulary decisions and competing binders.

The main commercial risks are:

• Rapid price erosion after additional generic entry.
• Conversion to iron-based or calcium-based binders.
• Patient discontinuation because of gastrointestinal intolerance.
• Tablet burden and poor adherence.
• Reimbursement pressure in dialysis-related payment systems.
• Manufacturing interruptions involving polymer supply or high-barrier packaging.

The most defensible revenue strategy is a portfolio rather than a single tablet SKU: conventional tablets for price-sensitive volume, powder for dysphagia and pediatric use, and a manufacturing or packaging advantage for institutional contracts.

Key Takeaways

• Sevelamer carbonate is a mature phosphate binder with expired core exclusivity and established generic competition.
• Excipient strategy should focus on hydration, dispersion, palatability, tablet robustness and manufacturing efficiency.
• Calcium, magnesium, aluminum, iron and phosphate-containing excipients require careful compatibility assessment.
• Powder formulations and smaller, easier-to-administer tablets offer the clearest commercial differentiation.
• The strongest residual IP opportunities involve specific formulation, process, particle-size, stability and packaging claims.
• Generic success depends more on cost, supply reliability and channel access than on active-ingredient novelty.
• Pediatric, dysphagia-friendly and unit-dose presentations offer higher-value niches than another conventional 800 mg tablet.
• Current Orange Book listings, paragraph IV certifications and litigation records must be reviewed product by product before launch or licensing decisions.

FAQs

Can sevelamer carbonate be formulated as a chewable tablet?

Yes, but a chewable formulation must address polymer taste, mouthfeel, tablet size, mechanical strength and dose uniformity. A chewable product would compete directly with established chewable phosphate binders and would need a clear tolerability or adherence advantage.

Which excipients should be avoided in sevelamer carbonate?

Phosphate-containing excipients and multivalent metal salts require particular caution. Calcium, magnesium, aluminum and iron compounds may alter phosphate availability, polymer interactions or co-administered drug binding.

Is powder sevelamer carbonate more commercially attractive than tablets?

Powder has stronger differentiation potential because it supports swallowing, pediatric administration and dose flexibility. Tablets remain important because they are familiar, portable and easier to dispense in high-volume dialysis channels.

Can a new excipient combination obtain patent protection?

Yes. Protection is more credible when the combination produces a measurable technical effect, such as improved suspension redispersion, reduced tablet dimensions, faster hydration, improved stability or lower dose variability. Routine substitution of one filler or lubricant is less likely to support strong claims.

Does sevelamer carbonate require a conventional dissolution test?

Conventional dissolution is not the sole performance measure because sevelamer acts locally and is not absorbed. Comparative phosphate-binding capacity, binding kinetics, hydration, dispersion and dose uniformity are central to product evaluation.

References

1. U.S. Food and Drug Administration. (2023). Renvela (sevelamer carbonate) prescribing information. Sanofi-Aventis U.S. LLC.
2. National Library of Medicine. (2024). DailyMed: Sevelamer carbonate tablets and powder for oral suspension. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59.
5. U.S. Food and Drug Administration. (2024). Electronic Orange Book patent and exclusivity information.